Download PDF
Digestive Disease Interventions 2017; 01(03): 184-194
DOI: 10.1055/s-0037-1604355
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Evidence-Based Review of Nonsurgical Management of Colorectal Cancer Liver Metastasis and Evolving Role of Interventional Radiology

Hanping Wu
1   Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio
,
Aman Opneja
2   Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio
,
Christopher Sutter
1   Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio
,
Indravadan Patel
1   Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio
,
Robert J. Lewandowski
3   Department of Radiology, Medicine, and Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
,
Jennifer Eads
2   Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio
,
Sidhartha Tavri
1   Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio
› Author Affiliations
Further Information

Publication History

02 May 2017

08 June 2017

Publication Date:
31 July 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Colorectal cancer is the third most common malignancy and the second leading cause of cancer death in the United States. Approximately 20 to 25% of patients have clinically detectable colorectal liver metastases (CLM) at the initial diagnosis, and nearly 50% of patients with colorectal cancer develop hepatic metastases at some point during the course of their disease. Patients with untreated CLM have a median survival time of approximately 4.5 months. For the resectable cases, surgical resection is the first-choice treatment. However, only 10 to 30% of patients with CLM are eligible for resection at presentation. There are several nonsurgical treatment options for patients with CLM who are not candidates for initial or potentially curative resection. These include systemic chemotherapy, locoregional therapy that includes thermal and nonthermal ablation, external beam radiation therapy, regional chemotherapy via the hepatic artery, and selective radioembolization using yttrium-labeled glass or resin microspheres. In this review, we discuss the nonsurgical treatment options described earlier that are part of the current multidisciplinary algorithm in the management of CLM and focus on the expanding role of interventional radiology.

Keywords

colorectal cancer - liver metastases - nonsurgical management
 

  • References

  • 1 National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Colon and Rectum Cancer. Available at: http://seer.cancer.gov/statfacts/html/colorect.html . Accessed July 17, 2017
    PubMedGoogle Scholar
  • 2 Garden OJ, Rees M, Poston GJ. , et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 (Suppl. 03) iii1-iii8
    PubMedGoogle Scholar
  • 3 Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141 (05) 586-589
    CrossrefPubMedGoogle Scholar
  • 4 Kanas GP, Taylor A, Primrose JN. , et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283-301
    CrossrefPubMedGoogle Scholar
  • 5 Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16 (08) 1311-1319
    CrossrefPubMedGoogle Scholar
  • 6 Nordlinger B, Van Cutsem E, Gruenberger T. , et al; European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20 (06) 985-992
    CrossrefPubMedGoogle Scholar
  • 7 Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999; 26 (05) 514-523
    PubMedGoogle Scholar
  • 8 Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 24 (31) 4954-4955
    CrossrefPubMedGoogle Scholar
  • 9 Bismuth H, Adam R, Lévi F. , et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224 (04) 509-520 , discussion 520–522
    CrossrefPubMedGoogle Scholar
  • 10 Gans D, Siegel C, Patel IJ, Tavri S, Madoff DC, Sutter C. Portal vein embolization in the treatment of metastatic colorectal cancer: optimal approach and current controversies. Dig Dis Interv 2017; 1 (03) 184-196
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 National Comprehensive Cancer Network. Clinical practice guidelines in Oncology (NCCN guidelines) colon cancer (version 1. 2017) (2016). Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf . Accessed November 23, 2016
    PubMedGoogle Scholar
  • 12 Heidelberger C, Chaudhuri NK, Danneberg P. , et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179 (4561): 663-666
    CrossrefPubMedGoogle Scholar
  • 13 Poon MA, O'Connell MJ, Moertel CG. , et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7 (10) 1407-1418
    CrossrefPubMedGoogle Scholar
  • 14 Saltz LB, Cox JV, Blanke C. , et al; Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343 (13) 905-914
    CrossrefPubMedGoogle Scholar
  • 15 Goldberg RM, Sargent DJ, Morton RF. , et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22 (01) 23-30
    CrossrefPubMedGoogle Scholar
  • 16 Tournigand C, André T, Achille E. , et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (02) 229-237
    CrossrefPubMedGoogle Scholar
  • 17 Colucci G, Gebbia V, Paoletti G. , et al; Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23 (22) 4866-4875
    CrossrefPubMedGoogle Scholar
  • 18 Souglakos J, Androulakis N, Syrigos K. , et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94 (06) 798-805
    CrossrefPubMedGoogle Scholar
  • 19 Falcone A, Ricci S, Brunetti I. , et al; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13) 1670-1676
    CrossrefPubMedGoogle Scholar
  • 20 Hoff PM, Ansari R, Batist G. , et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (08) 2282-2292
    CrossrefPubMedGoogle Scholar
  • 21 Cassidy J, Clarke S, Díaz-Rubio E. , et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26 (12) 2006-2012
    CrossrefPubMedGoogle Scholar
  • 22 Van Cutsem E, Köhne CH, Hitre E. , et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360 (14) 1408-1417
    CrossrefPubMedGoogle Scholar
  • 23 Van Cutsem E, Köhne CH, Láng I. , et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29 (15) 2011-2019
    CrossrefPubMedGoogle Scholar
  • 24 Douillard JY, Siena S, Cassidy J. , et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28 (31) 4697-4705
    CrossrefPubMedGoogle Scholar
  • 25 Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26 (01) 13-21
    CrossrefPubMedGoogle Scholar
  • 26 Di Nicolantonio F, Martini M, Molinari F. , et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26 (35) 5705-5712
    CrossrefPubMedGoogle Scholar
  • 27 Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (16) 3706-3712
    CrossrefPubMedGoogle Scholar
  • 28 Giantonio BJ, Catalano PJ, Meropol NJ. , et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12) 1539-1544
    CrossrefPubMedGoogle Scholar
  • 29 Grothey A, Van Cutsem E, Sobrero A. , et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863): 303-312
    CrossrefPubMedGoogle Scholar
  • 30 Mayer RJ, Van Cutsem E, Falcone A. , et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372 (20) 1909-1919
    CrossrefPubMedGoogle Scholar
  • 31 Le DT, Uram JN, Wang H. , et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372 (26) 2509-2520
    CrossrefPubMedGoogle Scholar
  • 32 Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003; 8 (06) 553-566
    CrossrefPubMedGoogle Scholar
  • 33 Herrmann KA, Waggershauser T, Sittek H, Reiser MF. Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems. Radiology 2000; 215 (01) 294-299
    CrossrefPubMedGoogle Scholar
  • 34 Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107 (04) 459-465
    CrossrefPubMedGoogle Scholar
  • 35 Kerr DJ, McArdle CS, Ledermann J. , et al; Medical Research Council's colorectal cancer study group; European Organisation for Research and Treatment of Cancer colorectal cancer study group. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003; 361 (9355): 368-373
    CrossrefPubMedGoogle Scholar
  • 36 Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 2007; 25 (35) 5649-5654
    CrossrefPubMedGoogle Scholar
  • 37 Van Cutsem E, Cervantes A, Adam R. , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (08) 1386-1422
    CrossrefPubMedGoogle Scholar
  • 38 Gillams A, Goldberg N, Ahmed M. , et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 2015; 25 (12) 3438-3454
    CrossrefPubMedGoogle Scholar
  • 39 Hammill CW, Billingsley KG, Cassera MA, Wolf RF, Ujiki MB, Hansen PD. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Ann Surg Oncol 2011; 18 (07) 1947-1954
    CrossrefPubMedGoogle Scholar
  • 40 Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2004; 14 (12) 2261-2267
    CrossrefPubMedGoogle Scholar
  • 41 Ruers T, Punt C, Van Coevorden F. , et al; EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23 (10) 2619-2626
    CrossrefPubMedGoogle Scholar
  • 42 Van Tilborg AA, Meijerink MR, Sietses C. , et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol 2011; 84 (1002): 556-565
    CrossrefPubMedGoogle Scholar
  • 43 Kim KH, Yoon YS, Yu CS. , et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 2011; 81 (01) 25-34
    CrossrefPubMedGoogle Scholar
  • 44 Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19 (05) 1206-1213
    CrossrefPubMedGoogle Scholar
  • 45 Wang X, Sofocleous CT, Erinjeri JP. , et al. Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases. Cardiovasc Intervent Radiol 2013; 36 (01) 166-175
    CrossrefPubMedGoogle Scholar
  • 46 Ginat DT, Saad W, Davies M, Walman D, Erturk E. Bowel displacement for CT-guided tumor radiofrequency ablation: techniques and anatomic considerations. J Endourol 2009; 23 (08) 1259-1264
    CrossrefPubMedGoogle Scholar
  • 47 Lee SJ, Choyke LT, Locklin JK, Wood BJ. Use of hydrodissection to prevent nerve and muscular damage during radiofrequency ablation of kidney tumors. J Vasc Interv Radiol 2006; 17 (12) 1967-1969
    CrossrefPubMedGoogle Scholar
  • 48 Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005; 242 (02) 158-171
    CrossrefPubMedGoogle Scholar
  • 49 Ogawa T, Kawamoto H, Kobayashi Y. , et al. Prevention of biliary complication in radiofrequency ablation for hepatocellular carcinoma-Cooling effect by endoscopic nasobiliary drainage tube. Eur J Radiol 2010; 73 (02) 385-390
    CrossrefPubMedGoogle Scholar
  • 50 Groeschl RT, Pilgrim CH, Hanna EM. , et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 2014; 259 (06) 1195-1200
    CrossrefPubMedGoogle Scholar
  • 51 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee Jr FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236 (01) 132-139
    CrossrefPubMedGoogle Scholar
  • 52 Carrafiello G, Laganà D, Mangini M. , et al. Microwave tumors ablation: principles, clinical applications and review of preliminary experiences. Int J Surg 2008; 6 (Suppl. 01) S65-S69
    CrossrefPubMedGoogle Scholar
  • 53 Izzo F. Other thermal ablation techniques: microwave and interstitial laser ablation of liver tumors. Ann Surg Oncol 2003; 10 (05) 491-497
    CrossrefPubMedGoogle Scholar
  • 54 Dupuy DE. Microwave ablation compared with radiofrequency ablation in lung tissue-is microwave not just for popcorn anymore?. Radiology 2009; 251 (03) 617-618
    CrossrefPubMedGoogle Scholar
  • 55 Correa-Gallego C, Fong Y, Gonen M. , et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol 2014; 21 (13) 4278-4283
    CrossrefPubMedGoogle Scholar
  • 56 Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat 2005; 4 (06) 699-705
    CrossrefPubMedGoogle Scholar
  • 57 Cannon R, Ellis S, Hayes D, Narayanan G, Martin II RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107 (05) 544-549
    CrossrefPubMedGoogle Scholar
  • 58 Hosein PJ, Echenique A, Loaiza-Bonilla A. , et al. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol 2014; 25 (08) 1233-1239.e2
    CrossrefPubMedGoogle Scholar
  • 59 Fiorentini G. A new tool to enhance the efficacy of chemoembolization to treat primary and metastatic hepatic tumors. Expert Opin Drug Deliv 2011; 8 (04) 409-413
    CrossrefPubMedGoogle Scholar
  • 60 Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009; 250 (01) 281-289
    CrossrefPubMedGoogle Scholar
  • 61 Albert M, Kiefer MV, Sun W. , et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117 (02) 343-352
    CrossrefPubMedGoogle Scholar
  • 62 Riemsma RP, Bala MM, Wolff R, Kleijnen J. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev 2013; (04) CD009498
    PubMedGoogle Scholar
  • 63 Kettenbach J, Stadler A, Katzler IV. , et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31 (03) 468-476
    CrossrefPubMedGoogle Scholar
  • 64 Fiorentini G, Aliberti C, Tilli M. , et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32 (04) 1387-1395
    PubMedGoogle Scholar
  • 65 Ranieri G, Niccoli Asabella A, Altini C. , et al. A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. Onco Targets Ther 2016; 9: 7527-7535
    CrossrefPubMedGoogle Scholar
  • 66 Padia SA, Lewandowski RJ, Johnson GE. , et al; Society of Interventional Radiology Standards of Practice Committee. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. J Vasc Interv Radiol 2017; 28 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 67 Seidensticker R, Denecke T, Kraus P. , et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35 (05) 1066-1073
    CrossrefPubMedGoogle Scholar
  • 68 Kennedy AS, Ball D, Cohen SJ. , et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol 2015; 6 (02) 134-142
    PubMedGoogle Scholar
  • 69 Saxena A, Meteling B, Kapoor J, Golani S, Morris DL, Bester L. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients. Ann Surg Oncol 2015; 22 (03) 794-802
    PubMedGoogle Scholar
  • 70 Gray B, Van Hazel G, Hope M. , et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12 (12) 1711-1720
    CrossrefPubMedGoogle Scholar
  • 71 van Hazel GA, Heinemann V, Sharma NK. , et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016; 34 (15) 1723-1731
    CrossrefPubMedGoogle Scholar
  • 72 Van Hazel G, Blackwell A, Anderson J. , et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88 (02) 78-85
    CrossrefPubMedGoogle Scholar
  • 73 Sharma RA, Van Hazel GA, Morgan B. , et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25 (09) 1099-1106
    CrossrefPubMedGoogle Scholar
  • 74 van Hazel GA, Pavlakis N, Goldstein D. , et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009; 27 (25) 4089-4095
    CrossrefPubMedGoogle Scholar
  • 75 Cosimelli M, Golfieri R, Cagol PP. , et al; Italian Society of Locoregional Therapies in Oncology (SITILO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103 (03) 324-331
    CrossrefPubMedGoogle Scholar
  • 76 Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 2015; 51 (14) 1927-1936
    CrossrefPubMedGoogle Scholar
  • 77 Martin II RC, Scoggins CR, Schreeder M. , et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121 (20) 3649-3658
    CrossrefPubMedGoogle Scholar
  • 78 Ruers T, Punt CJA, van Coevorden F. , et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). Ann Oncol 2015; 26 (suppl_4): iv114-iv115
    PubMedGoogle Scholar